) demonstrated that novel 6,8-difluoroquinolones were potent effectors of eukaryotic topoisomerase II. To determine the contribution of the C-8 fluorine to drug potency, we compared the effects of -(4-hydroxyphenyl)-1-cyclopropyl-4-quinolone-3-carboxylic acid] on the enzymatic activities of Drosophila melanogaster topoisomerase II with those of 953 (the 6,955). Removal of the C-8 fluoro group decreased the ability of the quinolone to enhance enzyme-mediated DNA cleavage -2.5-fold. Like its difluorinated counterpart, CP-115,955 increased the levels of cleavage intermediates without impairing the DNA religation reaction of the enzyme. Removal of the C-8 fluorine reduced the ability of the quinolone to inhibit topoisomerase II-catalyzed DNA relaxation. In addition, the cytotoxicity of CP-115,955 towards Chinese hamster ovary cells was decreased compared with that of CP-115,953. These results demonstrate that the C-8 fluorine increases the potency of quinolone derivatives against eukaryotic topoisomerase II and mammalian cells. Further comparisons of 804 (the N-1 ethyl-substituted derivative of the difluoro parent compound) indicate that the two intrinsic activities of quinolone-based drugs towards topoisomerase II (i.e., enhancement of DNA cleavage and inhibition of catalytic strand passage) can be differentially influenced by alteration of ring substituents. Finally, correlations between the biochemical and cytological activities of these drugs suggest that the ability to inhibit catalytic strand passage enhances the cytotoxic potential of quinolones towards eukaryotic cells.
Topoisomerase II is an essential enzyme (9, 21, 23, 53) that is required for chromosome structure (5, 13, 14, 16, 17) , condensation (1, 36, 52, 56) , and segregation (9, 23, 47, 54) . It also appears to play roles in DNA replication, transcription, and recombination in eukaryotic cells (3, 6, 8, 30, 39, 43, 47, 51, 55) .
In addition to its cellular functions, topoisomerase II is the primary target for several classes of antineoplastic drugs (32, 48, 59) . These agents are widely used for the treatment of human cancers (32, 48, 59) and their clinical efficacies correlate with their abilities to stabilize covalent enzymecleaved DNA complexes that are intermediates in the catalytic cycle of the enzyme (31, 32, 43, 48, 59) . Previous studies with etoposide (40, 46) and 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) (45, 46) demonstrated that these topoisomerase 1I-targeted drugs stabilize cleavage complexes primarily by inhibiting the ability of the enzyme to religate cleaved DNA.
Recent work indicates that the DNA cleavage complex of eukaryotic topoisomerase II is also a target for novel 6,8-difluoroquinolone derivatives (4, 44) . While quinolone-based drugs have been developed extensively as antimicrobial agents (targeted to DNA gyrase, the prokaryotic counterpart of topoisomerase II) (12, 24, 58) , these studies provided evidence that quinolones may have potential as antineoplastic drugs. One of the difluoro compounds examined, 6,8-difluoro-7-(4-hydroxyphenyl)-1-cyclopropyl-4-quinolone-3-carboxylic acid (CP-115,953) (see Fig. 1 ), was twice as potent as etoposide at enhancing topoisomerase II-mediated DNA cleavage (44) . In addition, the N-1 ethyl-substituted derivative of CP-115,953, CP-67,804, was -80% as potent as etoposide (46) . However, in contrast to previously characterized drugs, neither quinolone inhibited the religation reaction of the enzyme to a significant extent (44) . Thus, quinolone-based compounds in the CP-115,953 series may constitute a novel mechanistic class of topoisomerase IIdirected drugs.
The vast majority of clinically important quinolone antimicrobial agents are fluorinated in the C-6 position (7, 24) . This fluorine appears to be critical for potent quinolone action both in vitro and in vivo (7) . Although the requirement for the C-6 fluorine has been well established (7) , the importance of the C-8 fluoro group in 6,8-difluoroquinolones such as CP-115, 953 is not yet known. Therefore, the present study examined the effects of a novel quinolone derivative, CP-115,955, on the catalytic activities of Drosophila melanogaster topoisomerase II. This latter compound is identical to CP-115,953 except for the substitution of the C-8 fluorine with a hydrogen atom (see Fig. 1 ). On the basis of enzymatic and cytotoxicity assays, this substitution decreased the potency of the drug by 2.2-to 3.3-fold. This finding indicates that the presence of a fluorine in the C-8 position enhances quinolone action against eukaryotic topoisomerase II.
MATERIALS AND METHODS
Chemicals. DNA topoisomerase II was purified from the nuclei of 6-to 12-h-old D. melanogaster embryos by the procedure of Shelton et al. (49) . Negatively supercoiled bacterial plasmid pBR322 DNA was obtained from Escherichia coli DH1 by Triton X-100 lysis followed by double banding in cesium chloride-ethidium bromide gradients (33 25 mM NaCl, 50 mM KCl, 5 mM MgCl2, 0.1 mM EDTA, 2.5% glycerol). DNA cleavage/religation equilibria were established by incubating samples at 30°C for 6 min. Cleavage products were trapped (15) by the addition of 2 ,ul of 10% SDS. One microliter of 250 mM EDTA and 2 pl of a 0.8-mg/ml solution of proteinase K were added, and samples were incubated at 45°C for 30 min to digest topoisomerase II.
Final products were mixed with 2.5 pl of loading buffer (60% sucrose, 0.05% bromophenol blue, 0.05% xylene cyanol FF, 10 mM Tris-HCl [pH 7.9]), and the mixture was heated at 70°C for 1 min and subjected to electrophoresis in 40 mM Tris-acetate (pH 8.3) and 2 mM EDTA in 1% agarose (EM Science, Gibbstown, N.J.) gels. Following electrophoresis, DNA bands were stained in a 1-,ug/ml solution of ethidium bromide and visualized by transillumination with UV light (300 nm). DNA bands were photographed through Kodak 23A and 12 filters with Polaroid type 665 positive-negative film. The amount of DNA was quantitated by scanning negatives with an E-C Apparatus model EC910 scanning densitometer using Hoefer GS-370 Data System software. Under the conditions used, the intensity of the bands in the negatives was directly proportional to the amount of DNA present. The effects of drugs were examined over a concentration range of 0 to 150 ,uM. An amount of diluent equal to that in drug-containing samples was added to all control samples. None of the diluents affected the topoisomerase II-mediated DNA cleavage/religation equilibrium.
Heat-induced topoisomerase H-mediated DNA religation.
Reaction mixtures contained 50 to 100 nM topoisomerase II and 5 nM negatively supercoiled pBR322 DNA in a total volume of 20 p,l of cleavage buffer. Initial DNA cleavage/ religation equilibria were established at 30°C for 6 min. Topoisomerase II-mediated religation of cleaved DNA was induced by rapidly shifting samples from 30 to 55°C (27, 28, 42, 46) . Religation was terminated by the addition of SDS (1% final concentration) at various time points up to 20 s. Samples were treated with EDTA and proteinase K as described above. Reaction products were resolved by agarose gel electrophoresis and quantitated as described above. The effects of drugs on topoisomerase II-mediated DNA religation were examined by the addition of 100 ,uM CP-115,955, 50 p,M CP-115,953, or 100 ,uM etoposide to reaction mixtures. Drugs were added during the initial enzyme-DNA incubation. Control reaction mixtures contained amounts of diluent equivalent to those in drug-containing samples.
Topoisomerase II-mediated DNA relaxation. Assays were carried out as described by Osheroff et al. (41) . The effects of drugs were examined over a concentration range of 0 to 250 P,M.
Cytotoxicity of quinolone derivatives towards mammalian cells. Drug cytotoxicity was determined by a colony-forming assay (19, 44) . Wild-type Chinese hamster ovary (CHO) cells and VpmR-5 cells, a mutant CHO cell line selected for resistance against epipodophyllotoxins (19, 22) , were used for these studies. Cell lines were the generous gifts of R. Gupta and D. M. Sullivan. Cells were cultured as monolayers at 37°C under 5% CO2 in alpha-minimal essential medium (GIBCO-BRL, Gaithersburg, Md.) (without antibiotics) supplemented with 5% fetal calf serum.
RESULTS While most quinolone-based drugs are poor effectors of eukaryotic systems (12, 24, 58) , the difluoroquinolone derivative CP-115,953 has potent activity against eukaryotic topoisomerase II and mammalian cell lines (44) . Because of the antineoplastic potential of topoisomerase II-targeted agents (32, 48, 59) , it is important to understand the relative contributions of ring substituents to drug action. A previous study demonstrated that substitution of an ethyl for the cyclopropyl group in the N-1 position of CP-115,953 decreased its potency against eukaryotic topoisomerase II and mammalian cells by 2.5-to 22-fold (44) . To describe the contributions of the C-8 fluoro group to quinolone action, we examined the effects of CP-115,955 (in which the fluorine is substituted by a hydrogen atom) on D. melanogaster topoisomerase II. The structures of CP-115,955 and its parent compound, CP-115,953, are shown in Fig. 1 .
Effects of CP-115,955 on the DNA cleavage/religation equilibrium of topoisomerase II. The chemotherapeutic efficacies of topoisomerase II-targeted antineoplastic drugs correlate with their abilities to enhance enzyme-mediated DNA cleavage (i.e., to shift the DNA cleavage/religation equilibrium of the enzyme towards the cleavage event) (31, 32, 48, 59) . Topoisomerase II establishes cleavage/religation equilibria both before and after its double-stranded DNA passage event (38, 39, 43, 46) . Since strand passage requires ATP binding (39, 41, 43, 51, 55) , the pre-and post-strand passage equilibria of the enzyme can be separated experimentally. The DNA cleavage/religation equilibrium described here were established in the absence of ATP. Therefore, the following experiments examined the effects of CP-115,955 on the pre-strand passage equilibrium of the enzyme.
As determined by the increase in linear (form III) DNA, CP-115,955 was a less effective enhancer of topoisomerase II-mediated double-stranded DNA cleavage than was CP-115,953 (Fig. 2) . No drug-induced DNA breakage was observed in the absence of the enzyme. To quantitate differences in potencies, we examined the effects of these quinolones on the DNA cleavage/religation equilibrium of the enzyme over a range of drug concentrations (Fig. 3) [2, 24] ). The minimal concentration of the difluoro parent compound, CP-115,953, required to induce gyrase-mediated DNA cleavage was 0.22 ,uM. Thus, removal of the C-8 fluorine had little effect on the potency of the quinolone towards the prokaryotic enzyme. A similar observation was made previously by comparing the potencies of the C-8 fluoro derivatives of norfloxacin, perfloxacin, and ciprofloxacin with those of their parent compounds (10, 11 (44) . This finding suggests that these compounds enhance the levels of DNA breakage primarily by stimulating the forward rate of DNA cleavage. This is in marked contrast to the results obtained with topoisomerase II-targeted antineoplastic drugs such as etoposide (40, 46) and m-AMSA (45, 46) , which appear to stabilize cleavage intermediates primarily by inhibiting enzyme-mediated DNA religation. To determine whether the C-8 fluoro group influences the mechanism of quinolone action, we monitored the effects of CP-115,955 on the ability of topoisomerase II to religate cleaved DNA (prior to strand passage) by using a heat-induced DNA religation assay (27, 28, 42, 46) . This assay takes advantage of the fact that the religation reaction of topoisomerase II is less sensitive to variations in temperature than is its cleavage reaction (27, 28, 42, 46 Cytotoxicity of CP-115,955 towards CHO cell lines. To further assess the contributions of the C-8 position to quinolone action, we examined the cytotoxicity of CP-115,955 towards mammalian cells. Two tissue culture lines were used for this study. The first was a wild-type CHO cell line. The second was VpmR-5, a CHO cell line selected for resistance against epipodophyllotoxins (22) . Compared with CHO cells, VpmR-5 cells are 10-to 20-fold resistant to etoposide (a representative epipodophyllotoxin) (19, 22, 44) , and they show broad cross-resistance to a number of topoisomerase TI-targeted antineoplastic drugs (19, 22) . Drug resistance in this line results from the presence of a mutated, resistant type II enzyme, rather than a decrease in drug uptake (19, 22, 50) .
Substitution of a hydrogen atom for the C-8 fluorine decreased quinolone cytotoxicity towards wild-type CHO cells -2.2-fold ( Table 1 ). The effective concentration of CP-115,955 required to kill 50% of the cells (EC50) was -20 ,uM; that of the parent compound, CP-115,953, was -9 p,M (44) .
In a previous study, the Vpm"-5 line showed only low (2, 12, 24, 58) . Most members of this drug class show little potency against eukaryotic systems (12, 24, 58 Although the importance of the C-6 fluoro group to quinolone potency has been well documented (7) , little is known (9, 21, 23, 39, 43, 51, 53, 55) , it is tempting to speculate that the ability of quinolones to inhibit this activity contributes to their cytotoxic potential. It will be necessary to fully characterize the pharmacokinetic properties of these quinolone-based drugs, however, before correlations between this inhibitory activity and cell death can be firmly established.
The two intrinsic activities of quinolone-based drugs (i.e., enhancement of DNA cleavage and inhibition of catalytic strand passage) (12, 24, 58) can be differentially influenced by the alteration of ring substituents. Although substitutions at the C-8 and N-1 positions (Table 1) had similar effects on DNA cleavage, the N-1 substitution increased the IC50 of the quinolone for DNA relaxation to a greater extent. Given the relationships between DNA cleavage, DNA strand passage, and cytotoxicity, the ability to differentially alter drug activities by specific ring substitutions may significantly affect future quinolone design.
Gyrase-targeted quinolones have been developed exclusively as antimicrobial agents (2, 12, 24, 58) . Even the most potent gyrase-targeted drug in clinical use, ciprofloxacin, shows only limited activity towards eukaryotic topoisomerase 11 (4) . The series of fluoroquinolones described in Table 1 are novel in their high potency towards both gyrase and the eukaryotic type II enzyme. Considering the antineoplastic potential of these compounds, it is important to establish structureactivity relationships for different ring substituents within the series. The results of the present study indicate that the C-8 fluoro group contributes to the potency of these compounds against eukaryotic topoisomerase II and mammalian cells.
